Literature DB >> 4507516

Chemotherapy through lysosomes with a DNA-daunorubicin complex.

A Trouet, D Deprez-de Campeneere, C De Duve.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4507516     DOI: 10.1038/newbio239110a0

Source DB:  PubMed          Journal:  Nat New Biol        ISSN: 0090-0028


× No keyword cloud information.
  53 in total

Review 1.  Transfection of Enterobacteriaceae and its applications.

Authors:  R Benzinger
Journal:  Microbiol Rev       Date:  1978-03

2.  Inhibition of adriamycin cardiotoxicity by acetyldaunomycin.

Authors:  G Zbinden
Journal:  Experientia       Date:  1975-09-15

3.  Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy.

Authors:  A J Versluis; E T Rump; P C Rensen; T J Van Berkel; M K Bijsterbosch
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

4.  Comparative toxicity of detorubicin and doxorubicin, free and DNA-bound, for hemopoietic stem cells.

Authors:  M Huybrechts; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Poly(I).poly(C), a potential drug carrier for the antitumor agent mitoxantrone: in vitro drug binding study.

Authors:  H G Eichler; R Mader; B Blöchl-Daum; G Steger; H Rainer
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.

Authors:  A Trouet; M Masquelier; R Baurain; D Deprez-De Campeneere
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

7.  Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory.

Authors:  R Hulhoven; G Sokal; C Harvengt
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.

Authors:  A Trouet; D Deprez-De Campeneere
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

9.  Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells.

Authors:  C Paul; C Peterson; G Gahrton; D Lockner
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

10.  Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes.

Authors:  D Deprez-De Campeneere; R Baurain; M Huybrechts; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.